Menopause Drugs Market Size, Share & Industry Analysis, By Therapy Type (Hormonal Therapies {Estrogen-based therapies, Progestogen-based therapies, Combination therapies, and Others} and Non-Hormonal Therapies {Neurokinin receptor antagonists, SSRI/SNRI therapies Gabapentinoids, GSM therapies, and Others}), By Disease Indication (Vasomotor Symptoms (VMS), Genitourinary Syndrome of Menopause (GSM), Sleep Disturbances, Mood Disorders, Postmenopausal Osteoporosis, Sexual Dysfunction, and Others), By Route of Administration, By Distribution Channel, and Regional Forecast, 2026-2034

Last Updated: February 11, 2026 | Format: PDF | Report ID: FBI115407

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
4. Market Trends
Key Insights
1. Technological Advancements in the Market
2. Key Industry Developments – Mergers, Acquisitions, Partnerships etc.
3. New Product Launches, By Key Players
4. Regulatory Scenario, By Key Countries/Region
5. Genomic Studies Overview
Global Menopause Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Therapy Type
  1. Hormonal Therapies
    1. Estrogen-based therapies
    2. Progestogen-based therapies
    3. Combination therapies
    4. Others
  2. Non-Hormonal Therapies
    1. Neurokinin receptor antagonists
    2. SSRI/SNRI therapies
    3. Gabapentinoids
    4. GSM therapies
    5. Others
2. Market Analysis, Insights and Forecast – By Disease Indication
  1. Vasomotor Symptoms (VMS)
  2. Genitourinary Syndrome of Menopause (GSM)
  3. Sleep Disturbances
  4. Mood Disorders
  5. Postmenopausal Osteoporosis
  6. Sexual Dysfunction
  7. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Transdermal
  3. Vaginal
  4. Intrauterine
  5. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
5. Market Analysis, Insights and Forecast – Region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East & Africa
North America Menopause Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Therapy Type
  1. Hormonal Therapies
    1. Estrogen-based therapies
    2. Progestogen-based therapies
    3. Combination therapies
    4. Others
  2. Non-Hormonal Therapies
    1. Neurokinin receptor antagonists
    2. SSRI/SNRI therapies
    3. Gabapentinoids
    4. GSM therapies
    5. Others
2. Market Analysis, Insights and Forecast – By Disease Indication
  1. Vasomotor Symptoms (VMS)
  2. Genitourinary Syndrome of Menopause (GSM)
  3. Sleep Disturbances
  4. Mood Disorders
  5. Postmenopausal Osteoporosis
  6. Sexual Dysfunction
  7. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Transdermal
  3. Vaginal
  4. Intrauterine
  5. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
5. Market Analysis, Insights and Forecast – By Country
  1. U.S.
  2. Canada
Europe Menopause Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Therapy Type
  1. Hormonal Therapies
    1. Estrogen-based therapies
    2. Progestogen-based therapies
    3. Combination therapies
    4. Others
  2. Non-Hormonal Therapies
    1. Neurokinin receptor antagonists
    2. SSRI/SNRI therapies
    3. Gabapentinoids
    4. GSM therapies
    5. Others
2. Market Analysis, Insights and Forecast – By Disease Indication
  1. Vasomotor Symptoms (VMS)
  2. Genitourinary Syndrome of Menopause (GSM)
  3. Sleep Disturbances
  4. Mood Disorders
  5. Postmenopausal Osteoporosis
  6. Sexual Dysfunction
  7. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Transdermal
  3. Vaginal
  4. Intrauterine
  5. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
5. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. U.K.
  2. Germany
  3. France
  4. Italy
  5. Spain
  6. Scandinavia
  7. Rest of Europe
Asia Pacific Menopause Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Therapy Type
  1. Hormonal Therapies
    1. Estrogen-based therapies
    2. Progestogen-based therapies
    3. Combination therapies
    4. Others
  2. Non-Hormonal Therapies
    1. Neurokinin receptor antagonists
    2. SSRI/SNRI therapies
    3. Gabapentinoids
    4. GSM therapies
    5. Others
2. Market Analysis, Insights and Forecast – By Disease Indication
  1. Vasomotor Symptoms (VMS)
  2. Genitourinary Syndrome of Menopause (GSM)
  3. Sleep Disturbances
  4. Mood Disorders
  5. Postmenopausal Osteoporosis
  6. Sexual Dysfunction
  7. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Transdermal
  3. Vaginal
  4. Intrauterine
  5. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
5. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. China
  2. Japan
  3. India
  4. Australia
  5. Southeast Asia
  6. Rest of Asia Pacific
Latin America Menopause Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Therapy Type
  1. Hormonal Therapies
    1. Estrogen-based therapies
    2. Progestogen-based therapies
    3. Combination therapies
    4. Others
  2. Non-Hormonal Therapies
    1. Neurokinin receptor antagonists
    2. SSRI/SNRI therapies
    3. Gabapentinoids
    4. GSM therapies
    5. Others
2. Market Analysis, Insights and Forecast – By Disease Indication
  1. Vasomotor Symptoms (VMS)
  2. Genitourinary Syndrome of Menopause (GSM)
  3. Sleep Disturbances
  4. Mood Disorders
  5. Postmenopausal Osteoporosis
  6. Sexual Dysfunction
  7. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Transdermal
  3. Vaginal
  4. Intrauterine
  5. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
5. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. Brazil
  2. Mexico
  3. Rest of Latin America
Middle East & Africa Menopause Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Therapy Type
  1. Hormonal Therapies
    1. Estrogen-based therapies
    2. Progestogen-based therapies
    3. Combination therapies
    4. Others
  2. Non-Hormonal Therapies
    1. Neurokinin receptor antagonists
    2. SSRI/SNRI therapies
    3. Gabapentinoids
    4. GSM therapies
    5. Others
2. Market Analysis, Insights and Forecast – By Disease Indication
  1. Vasomotor Symptoms (VMS)
  2. Genitourinary Syndrome of Menopause (GSM)
  3. Sleep Disturbances
  4. Mood Disorders
  5. Postmenopausal Osteoporosis
  6. Sexual Dysfunction
  7. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Transdermal
  3. Vaginal
  4. Intrauterine
  5. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
5. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. GCC
  2. South Africa
  3. Rest of Middle East & Africa
Competitive Analysis
1. Global Market Share Analysis (2025)
2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability)
  1. Bayer
  2. Astellas Pharma
  3. Pfizer Inc.,
  4. Novo Nordisk
  5. Hisamitsu Pharmaceutical (Noven)
  6. Teva Pharmaceuticals Limited
  7. Viatris
  8. Amneal Pharmaceuticals
  9. AbbVie Inc.
  10. Organon

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
4. Market Trends
Key Insights
1. Technological Advancements in the Market
2. Key Industry Developments – Mergers, Acquisitions, Partnerships etc.
3. New Product Launches, By Key Players
4. Regulatory Scenario, By Key Countries/Region
5. Genomic Studies Overview
Global Menopause Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Therapy Type
  1. Hormonal Therapies
    1. Estrogen-based therapies
    2. Progestogen-based therapies
    3. Combination therapies
    4. Others
  2. Non-Hormonal Therapies
    1. Neurokinin receptor antagonists
    2. SSRI/SNRI therapies
    3. Gabapentinoids
    4. GSM therapies
    5. Others
2. Market Analysis, Insights and Forecast – By Disease Indication
  1. Vasomotor Symptoms (VMS)
  2. Genitourinary Syndrome of Menopause (GSM)
  3. Sleep Disturbances
  4. Mood Disorders
  5. Postmenopausal Osteoporosis
  6. Sexual Dysfunction
  7. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Transdermal
  3. Vaginal
  4. Intrauterine
  5. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
5. Market Analysis, Insights and Forecast – Region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East & Africa
North America Menopause Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Therapy Type
  1. Hormonal Therapies
    1. Estrogen-based therapies
    2. Progestogen-based therapies
    3. Combination therapies
    4. Others
  2. Non-Hormonal Therapies
    1. Neurokinin receptor antagonists
    2. SSRI/SNRI therapies
    3. Gabapentinoids
    4. GSM therapies
    5. Others
2. Market Analysis, Insights and Forecast – By Disease Indication
  1. Vasomotor Symptoms (VMS)
  2. Genitourinary Syndrome of Menopause (GSM)
  3. Sleep Disturbances
  4. Mood Disorders
  5. Postmenopausal Osteoporosis
  6. Sexual Dysfunction
  7. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Transdermal
  3. Vaginal
  4. Intrauterine
  5. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
5. Market Analysis, Insights and Forecast – By Country
  1. U.S.
  2. Canada
Europe Menopause Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Therapy Type
  1. Hormonal Therapies
    1. Estrogen-based therapies
    2. Progestogen-based therapies
    3. Combination therapies
    4. Others
  2. Non-Hormonal Therapies
    1. Neurokinin receptor antagonists
    2. SSRI/SNRI therapies
    3. Gabapentinoids
    4. GSM therapies
    5. Others
2. Market Analysis, Insights and Forecast – By Disease Indication
  1. Vasomotor Symptoms (VMS)
  2. Genitourinary Syndrome of Menopause (GSM)
  3. Sleep Disturbances
  4. Mood Disorders
  5. Postmenopausal Osteoporosis
  6. Sexual Dysfunction
  7. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Transdermal
  3. Vaginal
  4. Intrauterine
  5. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
5. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. U.K.
  2. Germany
  3. France
  4. Italy
  5. Spain
  6. Scandinavia
  7. Rest of Europe
Asia Pacific Menopause Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Therapy Type
  1. Hormonal Therapies
    1. Estrogen-based therapies
    2. Progestogen-based therapies
    3. Combination therapies
    4. Others
  2. Non-Hormonal Therapies
    1. Neurokinin receptor antagonists
    2. SSRI/SNRI therapies
    3. Gabapentinoids
    4. GSM therapies
    5. Others
2. Market Analysis, Insights and Forecast – By Disease Indication
  1. Vasomotor Symptoms (VMS)
  2. Genitourinary Syndrome of Menopause (GSM)
  3. Sleep Disturbances
  4. Mood Disorders
  5. Postmenopausal Osteoporosis
  6. Sexual Dysfunction
  7. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Transdermal
  3. Vaginal
  4. Intrauterine
  5. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
5. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. China
  2. Japan
  3. India
  4. Australia
  5. Southeast Asia
  6. Rest of Asia Pacific
Latin America Menopause Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Therapy Type
  1. Hormonal Therapies
    1. Estrogen-based therapies
    2. Progestogen-based therapies
    3. Combination therapies
    4. Others
  2. Non-Hormonal Therapies
    1. Neurokinin receptor antagonists
    2. SSRI/SNRI therapies
    3. Gabapentinoids
    4. GSM therapies
    5. Others
2. Market Analysis, Insights and Forecast – By Disease Indication
  1. Vasomotor Symptoms (VMS)
  2. Genitourinary Syndrome of Menopause (GSM)
  3. Sleep Disturbances
  4. Mood Disorders
  5. Postmenopausal Osteoporosis
  6. Sexual Dysfunction
  7. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Transdermal
  3. Vaginal
  4. Intrauterine
  5. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
5. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. Brazil
  2. Mexico
  3. Rest of Latin America
Middle East & Africa Menopause Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Therapy Type
  1. Hormonal Therapies
    1. Estrogen-based therapies
    2. Progestogen-based therapies
    3. Combination therapies
    4. Others
  2. Non-Hormonal Therapies
    1. Neurokinin receptor antagonists
    2. SSRI/SNRI therapies
    3. Gabapentinoids
    4. GSM therapies
    5. Others
2. Market Analysis, Insights and Forecast – By Disease Indication
  1. Vasomotor Symptoms (VMS)
  2. Genitourinary Syndrome of Menopause (GSM)
  3. Sleep Disturbances
  4. Mood Disorders
  5. Postmenopausal Osteoporosis
  6. Sexual Dysfunction
  7. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Transdermal
  3. Vaginal
  4. Intrauterine
  5. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
5. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. GCC
  2. South Africa
  3. Rest of Middle East & Africa
Competitive Analysis
1. Global Market Share Analysis (2025)
2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability)
  1. Bayer
  2. Astellas Pharma
  3. Pfizer Inc.,
  4. Novo Nordisk
  5. Hisamitsu Pharmaceutical (Noven)
  6. Teva Pharmaceuticals Limited
  7. Viatris
  8. Amneal Pharmaceuticals
  9. AbbVie Inc.
  10. Organon

Read Less

List of Figures

Figure 1: Global Menopause Drugs Market Revenue Breakdown (USD million, %) by Region, 2025 & 2034

Figure 2: Global Menopause Drugs Market Value Share (%), By Therapy Type, 2025 & 2034

Figure 3: Global Menopause Drugs Market Value Share (%), By Disease Indication, 2025 & 2034

Figure 4: Global Menopause Drugs Market Value Share (%), By Route of Administration, 2025 & 2034

Figure 5: Global Menopause Drugs Market Value Share (%), By Distribution Channel, 2025 & 2034

Figure 6: Global Menopause Drugs Market Value Share (%), by Region, 2025 & 2034

Figure 7: North America Menopause Drugs Market Value (USD million), By Therapy Type, 2025 & 2034

Figure 8: North America Menopause Drugs Market Value Share (%), By Therapy Type, 2025

Figure 9: North America Menopause Drugs Market Value (USD million), By Disease Indication, 2025 & 2034

Figure 10: North America Menopause Drugs Market Value Share (%), By Disease Indication, 2025

Figure 11: North America Menopause Drugs Market Value (USD million), By Route of Administration, 2025 & 2034

Figure 12: North America Menopause Drugs Market Value Share (%), By Route of Administration, 2025

Figure 13: North America Menopause Drugs Market Value (USD million), By Distribution Channel, 2025 & 2034

Figure 14: North America Menopause Drugs Market Value Share (%), By Distribution Channel, 2025

Figure 15: North America Menopause Drugs Market Value (USD million), by Country, 2025 & 2034

Figure 16: North America Menopause Drugs Market Value Share (%), by Country, 2025

Figure 17: Europe Menopause Drugs Market Value (USD million), By Therapy Type, 2025 & 2034

Figure 18: Europe Menopause Drugs Market Value Share (%), By Therapy Type, 2025

Figure 19: Europe Menopause Drugs Market Value (USD million), By Disease Indication, 2025 & 2034

Figure 20: Europe Menopause Drugs Market Value Share (%), By Disease Indication, 2025

Figure 21: Europe Menopause Drugs Market Value (USD million), By Route of Administration, 2025 & 2034

Figure 22: Europe Menopause Drugs Market Value Share (%), By Route of Administration, 2025

Figure 23: Europe Menopause Drugs Market Value (USD million), By Distribution Channel, 2025 & 2034

Figure 24: Europe Menopause Drugs Market Value Share (%), By Distribution Channel, 2025

Figure 25: Europe Menopause Drugs Market Value (USD million), by Country/ Sub-region, 2025 & 2034

Figure 26: Europe Menopause Drugs Market Value Share (%), by Country/ Sub-region, 2025

Figure 27: Asia Pacific Menopause Drugs Market Value (USD million), By Therapy Type, 2025 & 2034

Figure 28: Asia Pacific Menopause Drugs Market Value Share (%), By Therapy Type, 2025

Figure 29: Asia Pacific Menopause Drugs Market Value (USD million), By Disease Indication, 2025 & 2034

Figure 30: Asia Pacific Menopause Drugs Market Value Share (%), By Disease Indication, 2025

Figure 31: Asia Pacific Menopause Drugs Market Value (USD million), By Route of Administration, 2025 & 2034

Figure 32: Asia Pacific Menopause Drugs Market Value Share (%), By Route of Administration, 2025

Figure 33: Asia Pacific Menopause Drugs Market Value (USD million), By Distribution Channel, 2025 & 2034

Figure 34: Asia Pacific Menopause Drugs Market Value Share (%), By Distribution Channel, 2025

Figure 35: Asia Pacific Menopause Drugs Market Value (USD million), by Country/ Sub-region, 2025 & 2034

Figure 36: Asia Pacific Menopause Drugs Market Value Share (%), by Country/ Sub-region, 2025

Figure 37: Latin America Menopause Drugs Market Value (USD million), By Therapy Type, 2025 & 2034

Figure 38: Latin America Menopause Drugs Market Value Share (%), By Therapy Type, 2025

Figure 39: Latin America Menopause Drugs Market Value (USD million), By Disease Indication, 2025 & 2034

Figure 40: Latin America Menopause Drugs Market Value Share (%), By Disease Indication, 2025

Figure 41: Latin America Menopause Drugs Market Value (USD million), By Route of Administration, 2025 & 2034

Figure 42: Latin America Menopause Drugs Market Value Share (%), By Route of Administration, 2025

Figure 43: Latin America Menopause Drugs Market Value (USD million), By Distribution Channel, 2025 & 2034

Figure 44: Latin America Menopause Drugs Market Value Share (%), By Distribution Channel, 2025

Figure 45: Latin America Menopause Drugs Market Value (USD million), by Country/ Sub-region, 2025 & 2034

Figure 46: Latin America Menopause Drugs Market Value Share (%), by Country/ Sub-region, 2025

Figure 47: Middle East & Africa Menopause Drugs Market Value (USD million), By Therapy Type, 2025 & 2034

Figure 48: Middle East & Africa Menopause Drugs Market Value Share (%), By Therapy Type, 2025

Figure 49: Middle East & Africa Menopause Drugs Market Value (USD million), By Disease Indication, 2025 & 2034

Figure 50: Middle East & Africa Menopause Drugs Market Value Share (%), By Disease Indication, 2025

Figure 51: Middle East & Africa Menopause Drugs Market Value (USD million), By Route of Administration, 2025 & 2034

Figure 52: Middle East & Africa Menopause Drugs Market Value Share (%), By Route of Administration, 2025

Figure 53: Middle East & Africa Menopause Drugs Market Value (USD million), By Distribution Channel, 2025 & 2034

Figure 54: Middle East & Africa Menopause Drugs Market Value Share (%), By Distribution Channel, 2025

Figure 55: Middle East & Africa Menopause Drugs Market Value (USD million), by Country/ Sub-region, 2025 & 2034

Figure 56: Middle East & Africa Menopause Drugs Market Value Share (%), by Country/ Sub-region, 2025

Figure 57: Global Menopause Drugs Market Share (%), by Company, 2025

List of Tables

Table 1: Global Menopause Drugs Market Revenue (USD million) Forecast, By Therapy Type, 2021-2034

Table 2: Global Menopause Drugs Market Revenue (USD million) Forecast, By Hormonal Therapies, 2021-2034

Table 3: Global Menopause Drugs Market Revenue (USD million) Forecast, By Non-Hormonal Therapies, 2021-2034

Table 4: Global Menopause Drugs Market Revenue (USD million) Forecast, By Disease Indication, 2021-2034

Table 5: Global Menopause Drugs Market Revenue (USD million) Forecast, By Route of Administration, 2021-2034

Table 6: Global Menopause Drugs Market Revenue (USD million) Forecast, By Distribution Channel, 2021-2034

Table 7: Global Menopause Drugs Market Revenue (USD million) Forecast, by Region, 2021-2034

Table 8: North America Menopause Drugs Market Revenue (USD million) Forecast, By Therapy Type, 2021-2034

Table 9: North America Menopause Drugs Market Revenue (USD million) Forecast, By Hormonal Therapies, 2021-2034

Table 10: North America Menopause Drugs Market Revenue (USD million) Forecast, By Non-Hormonal Therapies, 2021-2034

Table 11: North America Menopause Drugs Market Revenue (USD million) Forecast, By Disease Indication, 2021-2034

Table 12: North America Menopause Drugs Market Revenue (USD million) Forecast, By Route of Administration, 2021-2034

Table 13: North America Menopause Drugs Market Revenue (USD million) Forecast, By Distribution Channel, 2021-2034

Table 14: North America Menopause Drugs Market Revenue (USD million) Forecast, by Country, 2021-2034

Table 15: Europe Menopause Drugs Market Revenue (USD million) Forecast, By Therapy Type, 2021-2034

Table 16: Europe Menopause Drugs Market Revenue (USD million) Forecast, By Hormonal Therapies, 2021-2034

Table 17: Europe Menopause Drugs Market Revenue (USD million) Forecast, By Non-Hormonal Therapies, 2021-2034

Table 18: Europe Menopause Drugs Market Revenue (USD million) Forecast, By Disease Indication, 2021-2034

Table 19: Europe Menopause Drugs Market Revenue (USD million) Forecast, By Route of Administration, 2021-2034

Table 20: Europe Menopause Drugs Market Revenue (USD million) Forecast, By Distribution Channel, 2021-2034

Table 21: Europe Menopause Drugs Market Revenue (USD million) Forecast, by Country/ Sub-region, 2021-2034

Table 22: Asia Pacific Menopause Drugs Market Revenue (USD million) Forecast, By Therapy Type, 2021-2034

Table 23: Asia Pacific Menopause Drugs Market Revenue (USD million) Forecast, By Hormonal Therapies, 2021-2034

Table 24: Asia Pacific Menopause Drugs Market Revenue (USD million) Forecast, By Non-Hormonal Therapies, 2021-2034

Table 25: Asia Pacific Menopause Drugs Market Revenue (USD million) Forecast, By Disease Indication, 2021-2034

Table 26: Asia Pacific Menopause Drugs Market Revenue (USD million) Forecast, By Route of Administration, 2021-2034

Table 27: Asia Pacific Menopause Drugs Market Revenue (USD million) Forecast, By Distribution Channel, 2021-2034

Table 28: Asia Pacific Menopause Drugs Market Revenue (USD million) Forecast, by Country/ Sub-region, 2021-2034

Table 29: Latin America Menopause Drugs Market Revenue (USD million) Forecast, By Therapy Type, 2021-2034

Table 30: Latin America Menopause Drugs Market Revenue (USD million) Forecast, By Hormonal Therapies, 2021-2034

Table 31: Latin America Menopause Drugs Market Revenue (USD million) Forecast, By Non-Hormonal Therapies, 2021-2034

Table 32: Latin America Menopause Drugs Market Revenue (USD million) Forecast, By Disease Indication, 2021-2034

Table 33: Latin America Menopause Drugs Market Revenue (USD million) Forecast, By Route of Administration, 2021-2034

Table 34: Latin America Menopause Drugs Market Revenue (USD million) Forecast, By Distribution Channel, 2021-2034

Table 35: Latin America Menopause Drugs Market Revenue (USD million) Forecast, by Country/ Sub-region, 2021-2034

Table 36: Middle East & Africa Menopause Drugs Market Revenue (USD million) Forecast, By Therapy Type, 2021-2034

Table 37: Middle East & Africa Menopause Drugs Market Revenue (USD million) Forecast, By Hormonal Therapies, 2021-2034

Table 38: Middle East & Africa Menopause Drugs Market Revenue (USD million) Forecast, By Non-Hormonal Therapies, 2021-2034

Table 39: Middle East & Africa Menopause Drugs Market Revenue (USD million) Forecast, By Disease Indication, 2021-2034

Table 40: Middle East & Africa Menopause Drugs Market Revenue (USD million) Forecast, By Route of Administration, 2021-2034

Table 41: Middle East & Africa Menopause Drugs Market Revenue (USD million) Forecast, By Distribution Channel, 2021-2034

Table 42: Middle East & Africa Menopause Drugs Market Revenue (USD million) Forecast, by Country/ Sub-region, 2021-2034

STUDY PERIOD: 2021-2034
BASE YEAR: 2025
HISTORICAL DATA: 2021-2024
NO OF PAGES: 180

Buy Now

Download Free Sample

Security Code

Growth Advisory Services

Clients

Get In Touch With Us

US +1 833 909 2966 ( Toll Free )

UK +44 808 502 0280 ( Toll Free )

+91 744 740 1245 (APAC)
sales@fortunebusinessinsights.com